Morgan Stanley raised the firm’s price target on Roche (RHHBY) to CHF 290 from CHF 255 and keeps an Underweight rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche price target raised to CHF 300 from CHF 290 at Berenberg
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- Vaccine committee considers changes to childhood schedule, NY Times reports
- Roche receives FDA clearance with CLIA waiver for pertussis point-of-care test
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK